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Abstract
Cell adhesion molecules play a central role at every step of the immune response. The function of
leukocytes can be regulated by modulating adhesion interactions between cell adhesion molecules
to develop therapeutic agents against autoimmune diseases. Among the different cell adhesion
molecules that participate in the immunological response, CD2 and its ligand CD58 (LFA-3) are
two of the best-characterized adhesion molecules mediating the immune response. To modulate
the cell adhesion interaction, peptides were designed from the discontinuous epitopes of the β-
strand region of CD2 protein. The two strands were linked by a peptide bond. β-Strands in the
peptides were nucleated by inserting a β-sheet-inducing Pro-Gly sequence with key amino acid
sequences from CD2 protein that binds to CD58. Using a fluorescence assay, peptides that
exhibited potential inhibitory activity in cell adhesion were evaluated for their ability to bind to
CD58 protein. A model for peptide binding to CD58 protein was proposed based on docking
studies. Administration of one of the peptides, P3 in collagen-induced arthritis (CIA) in the mouse
model, indicated that peptide P3 was able to suppress rheumatoid arthritis in mice.
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To generate the immune response, T-cell receptor (TCR) on the surface of T cells engages
with antigenic peptide:major histocompatibility complex (pMHC) on the surface of the
antigen-presenting cell (APC). This interaction is designated as Signal-1 (1–3). In addition,
the co-stimulatory signal (Signal-2) is delivered by cell adhesion molecules, including CD2–
CD58, LFA-1-ICAM-1 (CD11a/CD18–CD54), and CD28-B7 (CD28–CD80). Among the
different cell adhesion molecules that participate in an immunological response, CD2 and its
ligand CD58 (LFA-3) are two of the best-characterized. In the presence of CD2–CD58
interaction, T cells recognize correct pMHC with 50- to 100-fold greater affinity than in the
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absence of this interaction (1–4). Thus, a better understanding of the critical roles of CD2–
CD58 interaction in immune regulation and disease pathology provides an opportunity to
design new potential immunosuppressive agents. Inhibition of the CD2–CD58 interaction
has important implications in controlling immune responses in autoimmune diseases (5–7).
Therefore, molecules designed to inhibit CD2–CD58 interaction may function as
immunosuppressants.
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by
inflammation of the synovial lined joints. It is estimated that RA affects 1% of the US
population (8). It is an autoimmune disease with local tissue destruction and systemic
biochemical response. A hallmark of inflammatory arthritis is the accumulation of blood-
derived leukocytes within joints, granulocytes within synovial fluid, and mononuclear cells
in the synovial membrane. Cell adhesion molecules play a major role in pathogenesis of RA.
CD58 expression is dramatically up-regulated in inflammatory lesions, which further leads
to targeted recruitment of T cells into inflammatory sites (6). CD58 is widely distributed
among cell types of the synovial microenvironment and provides numerous cell types with
which lymphocytes can interact via CD2–CD58 and ICAM-1-LFA-1 adhesion pathways
during the course of inflammatory synovitis (9,10). RA-synovial fluid lymphocytes (SFL)
that consist mostly of T cells showed higher expression of CD2 and CD58 (11–12). It is
postulated that the onset of autoimmunity may be associated with CD58 up-regulation and
ligation of CD2 on dendritic cells; subsequent autocrine release of IL-1β increases the
release of IL-12 and, in turn, activates T cells. These findings make CD2 and CD58
molecules attractive targets for understanding the mechanism of autoimmune diseases.
Monoclonal antibodies (mAbs) that block the CD2–CD58 interaction are being developed to
treat autoimmune diseases. mAbs directed against CD2 inhibit T-cell adhesion or activation
(13–17). Alefacept is a recombinant human CD58-Ig fusion protein that effectively binds to
CD2 and prevents CD2 interaction with CD58 expressed on APC (5,18); Alefacept has
shown efficacy in a limited number of patients with psoriatic arthritis (PsA) (5,18–19).
However, therapeutic antibodies/fusion proteins often elicit significant side effects attributed
to their immunogenicity and are susceptible to enzymatic degradation. To circumvent these
problems, one approach is to design short peptides or small molecular mimics that will bind
to critical areas in target proteins and, like antibodies, interfere with their activity. Peptides
can be modified to protect the N- and C-terimini from enzymatic degradation (20–21).
In our previous studies, we have shown that peptides designed from the β-strand region of
CD2 protein block cell adhesion interactions between T-cells and epithelial cells (22–24).
Conformational constraints were introduced in the peptide by a Pro-Gly sequence and
cyclization to generate β-turn structures from the strand sequences (23). In the present work,
we describe the binding of CD2 peptides to CD58 protein. One of the designed peptides
called P3 was studied in detail for its in vivo activity using the collagen-induced arthritis
(CIA) mouse model. Results obtained from in vitro data indicated that peptides from CD2
bind to CD58 protein, and in vivo data suggested that the peptide P3 was able to suppress
RA in the mouse model. A model for the binding of CD2 peptide to CD58 protein was
proposed based on the docking studies.
Results and Discussion
Design of peptides
Design of the peptides was based on the structure of the CD2–CD58 complex and
mutagenesis reported in the literature (25–27). Upon examining the CD2 crystal structure
(Fig. 1A) in the CD2–CD58 complex (25), it was seen that the CD58 contact areas in CD2
involve the C, C', C" and F β-strands and the FG, CC', and C'C" loops. The CD2 epitopes
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are mapped in C, C', C" and F strands and two turns (FG loop and C" loop). Mutagenesis
studies of CD2/CD58 suggested that residues around the β-turn, β-strand (27) and flanking
residues of the β-turn at the interface between CD2 and CD58 are important for cell-cell
adhesion. In the CD2 protein, strands F and C are discontinuous in sequence (residues 29–36
and 82–89) but spatially close and form an anti-parallel β-sheet (Figures 1A &B) in which
strands are placed 5 Ǻ apart. Using mutagenesis studies, the residues in these strands have
been shown to be important for binding CD2 to CD58 protein (27). In our peptide design, by
retaining the C strand with D31, D32, and K34 residues that are close to the hydrophobic
region and the F strand with the “hot spot” Y86, the peptide mimics the native structure of
the protein.
Based on the results mentioned above and our previous studies (22–27), we proposed that a
cyclized β-hairpin peptide assembling the two strands (residues 31–34 and 84–87) (Figure
1B) would be a suitable model for mimicking the CD2 interface with CD58. While
designing the peptides, the following procedures were undertaken. A Pro-Gly sequence was
inserted to connect the two strands between D31 and D87; the other end of the strand (K34–
S84) was cyclized by different strategies to acquire a stable peptide structure (Figure
1B,Table 1). To design the control peptide, a 12-amino acid residue sequence was chosen
from the hot-spot region of CD2 (containing Tyr86) (22–24), and the sequence was
reversed. Tyr86 and Tyr81 were replaced with Ala to generate the control peptide (Table 1).
In our previous study, we reported that peptides derived from the CD2 protein β-strand
region were able to inhibit cell adhesion between Caco-2 cells and Jukat cells in a
concentration-dependent manner (23). At 180 µM, peptides 3 (P3), and 4 (P4) were able to
inhibit cell adhesion by nearly 70% compared to the control peptide. These peptides inhibit
the cell adhesion presumably by binding to CD58 protein and thus inhibiting CD2–CD58
interaction. In the present study, we provide the following evidence to show that peptides
from CD2 bind to CD58 protein on Caco-2 cells.
Binding of fluorescently labeled peptide to Caco-2 cells bearing CD58
In our preliminary studies, we have shown that CD2-derived peptides disrupt the T cell-
Caco-2 cell adhesion interaction. Here we want to show that CD2-derived peptides bind to
CD58 on the surface of Caco-2 cells. The expression of CD58 on the surface of Caco-2 cells
was confirmed by confocal microscopy using fluorescently labeled anti-CD58 (data shown
in Supporting Information). P3 and P4 have similar sequences but differ in the way they are
cyclized. P3 and P4 also have shown similar cell adhesion inhibition activity (23). P3 was
cyclized by main chain cyclization and, hence, the N-terminal was not available for FITC
labeling (side chain of Lys is available for FITC labeling). P4 was cyclized by side-chain
cyclization, and the main chain N-terminal was available for FITC labeling. Considering the
availability of free N-terminal, P4 was chosen for FITC-labeling. FITC-labeled P4 was
incubated with Caco-2 cells at different concentrations. The results of binding of P4 are
shown in Figure 2. The relative intensity of fluorescence with different P4 concentrations
clearly suggests the binding of P4 to Caco-2 cells. As a positive control, FITC-labeled anti-
CD58 was used. Statistical analysis of the data using one-way Anova analysis suggested
that, compared to the cells only, 100 µM (P< 0.05) and 50 µM (P<0.05) FITC-P4 showed
significant binding of P4 to Caco-2 cells, whereas 10 µM FITC-P4 did not show binding of
peptide to cells.
Microscopic studies were carried out to visually observe the binding of fluorescently labeled
P4 to Caco-2 cells. FITC-P4 and FITC-antiCD58 were incubated with Caco-2 cells and,
after washing and fixing, the cells were visualized using a fluorescence microscope. Figure
3A shows the binding of FITC-P4, and Figure 3B shows FITC-antiCD58 specifically
binding to CD58 protein. The binding of fluorescently labeled P4 and anti-CD58 was at the
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periphery of the cells, indicating the binding of P4 to CD58 protein. As a control, FITC was
used and non-specific binding of FITC was observed.
Antibody binding inhibition assay
The experiments described above suggest that CD2 peptides bind to CD58-expressing
Caco-2 cells; this is only indirect evidence that CD2 peptides bind to CD58 protein to inhibit
CD2–CD58 interaction. Thus, the objective of this experiment was to evaluate whether CD2
peptides inhibit anti-CD58 binding to CD58 expressed on the surface of Caco-2 cells.
Peptide 3 or 4 was incubated with Caco-2 cells followed by incubation with FITC-anti-
CD58 that blocks the CD58 binding region to CD2. The results indicate the competitive
binding nature of the peptides to CD58 protein (Figure 4); peptides P3 and P4 inhibit the
antibody binding by nearly 40 and 50% respectively. Statistical analysis suggested that there
is a significant difference in inhibition of anti-CD58 between P3 and P4 compared to control
peptide (P<0.05). There was no statistical difference between P3 and P4 in inhibiting
antibody binding to Caco-2 cells (P>0.05). From these experiments, one can conclude that
CD2 peptides bind to CD58 in the region where anti-CD58 binds and, hence, they inhibit the
interaction between CD2 and CD58.
Competitive binding of anti-CD58 and FITC-P4
To evaluate whether peptide P4 competes with anti-CD58 binding to CD58 on Caco-2 cells,
experiments were performed in which anti-CD58 was incubated at a constant concentration
with Caco-2 cells and then different concentrations of FITC-P4 were added. Binding of 100
µM FITC-P4 in the absence of anti-CD58 was used as a control. Compared to 100 µM
FITC-P4 in the absence of anti-CD58, 100 µM FITC-P4 in the presence of anti-CD58 has
lower binding affinity to the cells, suggesting that P4 has similar binding site with the mAb
on CD58 (Figure 5). In the presence of mAb and various concentrations of FITC-P4, the
FITC-P4 binding was concentration-dependent, and 200 µM FITC-P4 in the presence of
mAb has similar binding affinity to FITC-P4; this further confirms the blocking of FITC-P4-
binding to CD58 by mAb (Figure 5). Statistical analysis of the results suggested that there is
no significant difference between binding of 200 µM FITC-P4 in the presence of anti-CD58
and 100 µM FITC-P4 in the absence of anti-CD58 (P>0.05), whereas there was a significant
difference between 100 (P value = 0.05) and 50 µM FITC-P4 in the presence of antibody
and 100 µM FITC-P4 in the absence of antibody (P< 0.05). Competitive binding
experiments with various concentrations of anti-CD58 (1.25, 12.5, and 18.5 µg/mL) and a
constant amount of FITC-P4 (100 µM) suggested that binding of FITC-P4 decreased with an
increase in anti-CD58 concentration (Supporting Information). It should be noted that the
antibody has high specificity and high affinity toward CD58. The concentration of the
antibody used was much lower than that of the peptide P4. Overall, the antibody binding
inhibition studies indicated that a peptide from CD2 (P4) binds to CD58 at on the cell
surface in concentration-dependent manner.
Cell viability assay
Peptides P2 to P4 were also tested for their toxicity using the MTT assay (28–29). Peptides
were added to Caco-2 or Jurkat cells at different concentrations and incubated for 2 h, which
is the time of exposure of Caco-2 and Jurkat cells during the cell adhesion assay. The results
from viability assay on Caco-2 cells are shown in Figure 6. The cells treated with peptides
2–4 demonstrated 90–100% viability, indicating that these peptides were not toxic to cells
and that the observed inhibition data were not due to peptide toxicity.
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NMR spectroscopic method to determine binding of CD2 peptides to CD58 protein
Although the methods above detect the binding of CD2 peptides to CD58, they require
labeling of peptides with FITC. Because these peptides are small, labeling with FITC may
affect the conformation and activity of the peptide. Hence, a method that does not use FITC
labeling of peptides will serve as a complement to the methods described above. In this
method, the 1D NMR resonances of the CD2 peptides will be monitored upon titrating
CD58 protein at different concentrations. Depending on the kinetics of the binding between
peptide and protein, the ratio of concentration of protein to peptide, 1D NMR resonances of
the peptide will be changed (broadened or change in the intensity of the resonances) if the
peptide binds to the protein (30–31).
Figure 7A shows the amide region of the 1D NMR spectrum of P3 with and without the
protein at pH 7.0. There is a slight increase in the intensity of P3 resonances upon the
addition of protein CD58 (ratio of protein to peptide concentration was 1:80, because of
limited quantity of pure protein, high ratio was used). Small peptides with solvent-accessible
protons show very low intensity amide resonances at pH 7.0 because of the high exchange
rate of amide protons at neutral pH (32). Upon binding to protein, the rates of exchange of
many solvent accessible protons with water are decreased and, hence, the NMR resonance
intensity of amide protons increases. This slight increase in intensity can be used as a
method to detect binding of peptides to proteins. Upon binding of peptide to large molecule
(i.e., protein), the resonances of the small peptide are broadened. Figure 7A indicates that
there is a broadening of one of the NMR resonances of the peptide upon the addition of
protein CD58 (inset), suggesting that P3 binds to CD58 protein. Figure 7B shows the NMR
spectrum of control peptide without and with protein CD58 pH 7.0. The control peptide
(Table 1) did not show any amide resonances at pH 7.0 because of the rapid exchange rate
of amide protons. Similarly, upon addition of protein CD58, there is no indication of amide
resonances in the NMR of control peptide, indicating that control peptide does not bind to
protein CD58. Taken together, these results imply that the observed binding of P3 to CD58
protein is specific.
Docking studies
From the cellular assays, fluorescence microscopy studies, and NMR studies, it is clear that
P3 and P4 peptides have specificity toward CD58 protein. To model the interaction of P3
and P4 with CD58 protein domain I, docking (33) of three-dimensional structures P3 and P4
with CD58 protein crystal structure was carried out.
Docking of P3 to CD58—Fifty low energy docked structures of P3 with CD58 protein
were analyzed. Clusters of docked molecules were created based on docking energy, using
2.5 kcal/mol as error criterion in autodock 4 (33). Two clusters of docked molecules with
low energy were identified, cluster 1 with docking energy ranging from −14 to −12 kcal/mol
and cluster 2 from −9 to −11 kcal/mol. These two possible clusters of docking modes of P3
are shown in Figure 8A. Although cluster 1 had the lowest energy of docking, the bound
conformations were partially covering the CD2 binding surface of CD58 protein. However,
cluster 2 conformers were covering the binding surface of CD2–CD58 interaction on CD58
protein. Detailed interaction of one of the low energy docked structures from cluster 2 is
shown in Figure 8B. P3 interacts with protein CD58 by hydrogen bonding between the side
chain of Asp4 of P3 and the side chain of K34 of CD58. K34 of CD58 side chain also
formed a hydrophobic interaction with Tyr3 of P3 peptide. A hydrophobic interaction was
also possible between Pro5 of the peptide to F46 of CD58. In CD2–CD58 interaction, K34
seems to play a major role (27). The peptide structure had a β-turn at Asp4-Pro5-Gly6-Asp7
stabilized by intramolecular hydrogen bonding between the C=O of Asp4 to NH of Asp7.
This β-turn exposes the residues in the proper orientation to the CD58 protein for
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interaction. The proper orientation of important amino acid residues, the secondary structure
of the peptide 3 may be responsible for the biological activity exhibited by P3.
Docking of P4 to CD58—The results from docking of P4 on CD58 were similar to those
obtained from P3-CD58 docking with cluster 1 with low energy partially covering the CD2–
CD58 interacting surface. As mentioned above, P3 and P4 have similar sequences but differ
in cyclization method. The side chain of Asp7 formed a hydrogen bond with the backbone
of K32 of CD58; the side chain of Tyr 3 of P4 formed a hydrogen bond with R44 of CD58.
Both Pro5 and Tyr3 of P4 interact with the K34 aliphatic group and the F46 aromatic group,
forming a hydrophobic pocket (Supporting Information). Docking results indicated that the
overall interactions of CD58 with P3 or P4 are similar.
In vivo studies
The efficacy of the peptides from CD2 to suppress rheumatoid arthritis was evaluated in the
CIA mouse model (8,34,35). Peptide P3 was chosen for in vivo studies. P3 and P4 also have
shown similar cell adhesion inhibition activity (23). P3 was cyclized by main chain
cyclization and, hence stable against enzymatic degradation. Arthritis was induced in female
DBA/1 mice (Harlan Labs, Indianapolis, IN) by immunization twice with collagen-II (CII)
in Freund’s adjuvant as described in experimental section. Grouping of animals is shown in
Table 2. Between days 25 and 30 after the first collagen injection (day 0), swelling of the
joints was observed in mice treated with CII. In contrast, no changes in the joints were
observed for animals in the control group, which did not receive CII. A comparison of the
hind limbs of a normal (G1 group) (Supporting Information, Figure 6A) and an arthritic
mouse (G2 group) indicated severe inflammation in the arthritic mouse. There was
generalized swelling of the lower extremities in the region of the tarsus and digital bones of
the feet. Significant enlargement of the joint between the proximal and middle phalanx of
the forth digit of the right hind foot is evident (data shown in Supporting Information, Figure
6B). The ability of peptide P3 to suppress CIA was evaluated by visual observation of limbs
and by measuring the swelling of paws using a plethysmometer (34,36). To demonstrate the
suppression of arthritis with P3 peptide, we have plotted the data for G3, G4 and G5 mice
groups. Figure 9 shows the volume of water displaced by the swollen paws for the P3-
treated mice (G4 group) and control peptide mice (G3 group) (36). It is evident from Figure
9 that P3-treated mice showed a reduction in the swelling and had a delayed onset of disease
after day 30 compared to mice injected with control peptide (G3 group). Statistical analysis
suggests significant differences between mice treated with P3 (G4) and control peptide (G3)
(P < 0.01, through days 39–44), as well as between P3-treated mice and PBS-treated mice
(G5) (P < 0.01, through days 39–44).
After 55 days, the mice were sacrificed and histopathology of the hind limbs was completed.
Representative tissue sections taken from each group of mice are shown in Figure 10. For
simplicity we will discuss mice groups G1, G2, and G4. A normal phalangeal joint of the
hind foot of a control mouse (G1 group) without intradermal injection of type II collagen
(CII) is shown in Figure 10A. Cartilaginous surfaces are intact and smooth (arrows) with
normal synovium (arrowheads) and clear joint space (*). Mice injected with CII without
further treatment (G2 group) manifested severe arthritis as shown in Figure 10B. There was
marked cartilage and bone erosion. The synovium and synovial stroma were markedly
thickened by granulation tissue and infiltrated with mixed inflammatory cells, including
lymphocytes, macrophages, and fewer neutrophils. The articular spaces commonly
contained tissue ditritus, fibrin, and mixed inflammatory cells. Arthritis mice treated with P3
(G4 group) showed milder degenerative joint changes, microscopically. There was some
erosion of the articular cartilage of phalanges with minimal to mild hyperplasia of the
synovium, but, in contrast, mice in this treatment group lacked both significant pannus and
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inflammatory exudate (Figure 10C). The results from in vivo studies suggest that peptide P3
delays or suppresses RA in mice presumably by immunomodulation.
Conclusions and Future Directions
Peptides designed from the epitopes of the adhesion domain of CD2 protein inhibit cell
adhesion interaction, and a conformationally constrained P3 peptide derived from CD2
binds to CD58 protein. A working model for peptide binding to CD58 protein was proposed
based on the docking studies, which suggest that peptide P3 binds to CD58. Because P3 can
block CD2–CD58 interactions, peptide P3 has the ability to suppress RA in the CIA mouse
model. Future studies will be focused on modification of peptide P3 to enhance its efficacy
by incorporating β-strand inducing organic moieties. Modifications in the peptide include
introduction of Pro-(D)-Pro sequence and dibenzofuran moiety (37–39) at the β-turn region
to induce β-strand in the peptide structure and also to stabilize the peptide against enzymatic
degradation. This modification will be guided using the data from binding studies of P3 to
CD58 using transfer NOE data in future studies.
Experimental
Peptides
The linear control peptide (Table 1) was designed and synthesized, and the cyclic peptides
were purchased from Aroztech, LLC (Cincinnati, OH). The pure products were analyzed by
HPLC, electrospray mass spectrometry (ESI-MS). and high resolution mass spectrometry
(HR-MS). The HPLC chromatogram showed that the purities of the peptides were more than
90%, and ESI-MS showed the correct molecular ion for the peptides.
Cell Lines
The human colon adenocarcinoma cell lines (Caco-2) were obtained from the American
Type Culture Collection (Rockville, MD). Caco-2 cells were maintained in minimum
essential medium-α containing 10% FBS, 1% nonessential amino acids, 1 mM Na-pyruvate,
1% L-glutamine, and 100 mg/L of penicillin/streptomycin.
Fluorescence assay
Caco-2 cells were plated at a density of 1 × 104 cells/well in a 96-well tissue culture plate
and were incubated at 37°C with 5% CO2 for 24 hours. Various concentrations of FITC-P4
peptide (100 µM, 50 µM, and 10 µM), FITC, and FITC-anti-CD58 were prepared in PBS
and diluted in PBS for appropriate concentrations. 100 µL of peptide, anti-CD58, and FITC
were added to the well plates in triplicate. After the plates were incubated for 2 hours at
room temperature and washed three times with deionized water, fluorescence was quantified
using a fluorescence plate reader (FLx800, BioTek, Winooski, VT) with an excitation
wavelength of 485 nm and emission wavelength at 535 nm. Statistical analysis of the data
was performed by using JMP4 software (Texas Instruments, Cary, NC). One-way Anova
analysis was performed on the data, and P values were calculated by comparing each data
point at a particular concentration of FITC-P4 to data from cells only.
Fluorescence Microscopy
Green fluorescence emitted by the cell suspensions as well as fixed cells was examined
under a fluorescence microscope (Olympus America Inc., Center Valley, PA) at 20× and
40× magnification. Cell suspensions prepared for microplate reading were observed under
the microscope. For fixing the cells on slides, the following procedure was used. About
20,000 cells/mL of Caco-2 cells in appropriate medium were plated in each well of the
multichamber slide and incubated for about 24 hours. At the end of the incubation period,
Satyanarayanajois et al. Page 7













cells were fixed with 100% methanol kept at a temperature of −20°C. The wells were dried
at the end of 5 minutes and washed twice with PBS. Peptides and anti-CD58 stock solutions
were prepared in PBS. 150–200 µL of different concentrations of peptide, FITC, and FITC-
labeled antibody were added to the appropriate washed wells and incubated for about 2
hours. Dilutions of peptides, FITC, and FITC-labeled antibody were made in 2% normal
blocking serum solution. At the end of 2 hours, cells were washed three times with PBS. 2%
normal blocking serum solution was added. The wells were washed twice with PBS at the
end of 30 minutes. The slide was then mounted with the fluorescence mounting medium and
the images observed for fluorescence. Photographs were taken with 20× magnification. For
final presentation, images from fixed cells were used.
Antibody binding inhibition assay
The objective of this experiment was to show that peptides derived from CD2 inhibit the
binding of fluorescently labeled anti-CD58 with CD58 expressing Caco-2 cells. Stock
solutions of peptides were prepared by dissolving the peptides in PBS and diluting with PBS
to obtain the desired concentration. About 1 × 104 Caco-2 cells were seeded in 96-well
plates and incubated with 180 µM of P3 and P4 peptides for 1 h. Unbound peptide was
removed by washing with PBS three times. Anti-CD58-FITC (2 µg/mL in PBS) (BD
Biosciences, PharMingen, MD) was added to the cells, followed by incubation for 1 h. After
incubation, unbound anti-CD58-FITC was removed by washing with PBS three times. The
associated monolayer was lysed with 2% Triton X-100 in 0.1 M NaOH. 96-well plates for
reading in a microplate fluorescence analyzer (Biotek) were prepared. Plates were read with
an excitation wavelength of 485 nm and emission wavelength of 535 (±20) nm. Caco-2 cells
without the peptide and a control peptide were used as controls. Values plotted are the mean
of three independent experiments. P-value was calculated by comparing inhibition of P3 and
P4 with control peptide.
Competitive binding of anti-CD58 and FITC-labeled P4 peptide to Caco-2 cells
The objective of this experiment was to evaluate the binding of FITC-labeled P4 to Caco-2
cells in the presence of anti-CD58. Experiments were carried out using different amounts of
anti-CD58 with FITC-P4 at a fixed concentration, and at a fixed concentration of anti-CD58
and different amounts of FITC-P4. Antibody and FITC-labeled peptide solutions were
prepared in PBS at desired concentrations. For the first set of experiments, about 1 × 104
Caco-2 cells were seeded in 96-well plates and, after confluency, the cells were incubated
with 1.25, 12.5, and 18.5 µg/mL concentrations of anti-CD58 for 1 h. Cells with only PBS
and 100 µM of FITC-peptide in the absence of anti-CD58 were used as controls. After
washing with PBS, 100 µL of FITC-labeled P4 was added in PBS and the cells were
incubated for 1.5 hour. At the end of the incubation period, the cells were washed three
times with PBS and 100 µL of fresh PBS was added to each well. The plate was read in a
fluorescence plate reader with an excitation wavelength of 485 nm and emission wavelength
of 535 (±20) nm. Values of fluorescence were subtracted from fluorescence due to cells only
and plotted as the mean of three independent experiments.
In a second set of experiments, a fixed amount of anti-CD58 was added to wells with Caco-2
cells as mentioned above. After incubating the plate for 1 hr with 6.25 µg/mL of anti-CD58
and washing with PBS, different concentrations of FITC-P4 (200, 100, 50 and 10 µM) were
added to each well. Cells with only PBS and 100 µM of FITC-peptide in the absence of anti-
CD58 were used as controls. After incubation (1.5 hr) and washing, the plate was read in a
fluorescence plate reader with an excitation wavelength of 485 nm and emission wavelength
of 535 (±20) nm. Values of fluorescence were subtracted from the fluorescence due to cells
only and plotted as the mean of three independent experiments. Statistical analysis of the
data was carried out, and P values were used for comparison.
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Peptides that exhibited effects on Jurkat-Caco-2 adherence were tested by MTT (28) and/or
CellTiter-Glo assay (Promega Corporation Madison, WI) (29) to determine if their effects
were due to toxicity. Peptide stock solutions were prepared in water and diluted with serum-
free medium to obtain the desired concentration. Different concentrations (180, 150, 120,
and 90 µM) of peptide were added to Caco-2 cells and incubated for 1.5 hours, which is the
maximum time of exposure of Caco-2/Jurkat cells during the adherence assay. The cell
viabilities were validated by CellTiter-Glo assay. After the compounds were incubated with
cells, the wells were washed with PBS, and 100 µL of CellTiter-Glo reagent was added to
cells containing 100 µL medium. The plates were equilibrated for 10 minutes, and
luminescence from the cells with and without the compounds was read on a Biotek
microplate reader using blank cells with 0.1% SDS and 1% DMSO. The luminescence
values obtained at each concentration (triplicates for each run and two independent runs
were carried out) were averaged and adjusted by subtraction of blank values (wells without
cells). Cell viabilities were calculated.
NMR Spectroscopy
The sample for the NMR spectrum of P3 peptide was prepared by dissolving 1 mg of the
peptide in 0.7 mL of 90% H2O/10% D2O. The pH of the sample was adjusted to 7.0 by
adding aliquots of NaOD in D2O. One-dimensional NMR experiments were performed on a
700 MHz Spectrometer. Spectra were acquired at 291 K unless otherwise specified. For
peptide P3, protein CD58 interaction studies, titration of protein CD58, was carried out by
adding 10 µL of protein (recombinant CD58 protein, extracellular domain, R & D Systems,
Minneapolis, MN) sample directly into the NMR tube containing peptide P3. The maximum
total volume added was 50 µL, and the concentration of protein was 20 µM. 1D-NMR was
acquired for different protein–to-peptide concentration ratios (1:1000 to 1: 80). Experiments
were repeated for a control peptide (Table 1).
Docking
Docking of P3 and P4 peptides to CD58 protein was performed using AUTODOCK
software (33). CD58 crystal structure was obtained from a protein databank (1QA9). The
crystal structure of the complex of CD2–CD58 was downloaded, and CD2 molecule and
solvent molecules were removed from the pdb file. Polar hydrogen atoms were added to the
structure. A grid box with dimensions of 128×128×128 Å3 was used for calculations
covering the residues 22–32 and CD2 binding surface of CD58 protein. Three-dimensional
structures of P3 and P4 were determined as described earlier (23). Structures of P3 and P4
were saved as mol2 files and converted to pdbqt files in Autodock using Autodock tools.
Ligands P3 and P4 were made flexible for docking calculations, which were performed in
two stages. First, a trial was carried out with 10 runs and 250 thousand energy evaluations.
In the second stage, 100 runs with 25 million evaluations were carried out using Lamarkian
genetic algorithm for docking. Docking calculations were performed on Linux cluster on
high performance supercomputers at LSU Baton Rouge. Docked structures were listed in
increasing order of energy, and low energy clusters were used as the most probable binding
models. Structures from low energy docking were displayed and analyzed using PyMol
software (40). Amino acids from the peptide are designated with three-letter codes and
amino acids from protein are designated with one-letter codes in the text for the sake of
clarity.
In vivo studies
Female DBA/1 mice were obtained from Harlan Labs (Indianapolis, IN) for in vivo studies.
Mice were placed into five groups with 12 mice in each group (Table 2) (G1-control, G2-
Satyanarayanajois et al. Page 9













arthritic mice, G3-arthritic mice treated with control peptide (note that the control peptide
used in this case was CII-3 (QYMRADEADSTLR), a peptide that does not exhibit any RA
suppression activity as reported earlier) (41), G4-arthritis mice treated with peptide P3, G5-
arthritis mice treated with PBS. Out of 12 mice in each group, 8 mice were used for arthritis
scoring and 4 mice were used for histopathology analysis. RA was induced in mice by
intradermal injection of type II (CII) collagen formulation (CII emulsified in Freund’s
complete adjuvant, CFA) using published procedures (8,34,35). The emulsion, containing
100 µg of CII (in 100 µL of formulation), was injected intradermally at the base of the tail
for the first immunization. After 21 days, an emulsion of the same concentration (with
incomplete Freund’s adjuvant, IFA) was made and injected intra-dermally as the second
immunization (34,35). Peptide P3 and control peptide were dissolved in PBS and diluted
with PBS to obtain the desired concentrations. From the 22nd day to the 32nd day, the mice
were injected with control peptide or P3 (Table 1) on alternate days (5 injections, daily
dosing was not possible because of scarring in tail vein). Peptides or PBS were injected via
i.v. route at the tail vein. The dosage of the peptide was 2.5 mg/kg in 100 µL total volume of
PBS. All the mice were observed from day 21 to day 55 for signs of arthritis. The visual
appearance of the limbs was graded on a scale of 0–4 as well as by measuring the swelling
of limbs using a plethysmometer (34,36). Plethysmometer is a microcontrolled volume
meter, specially designed for accurate measurement of the rat/mouse paw swelling. The
amount of water displaced due to the swelling of the limbs is an accurate method of
objectively measuring the severity and the progression of the disease. The more swollen the
limbs are, the more water is displaced. The change in the total volume displaced by the four
limbs for each mouse was compared to baseline (no disease) (36). For final representation,
graphs were plotted with change in volume of water with swelling of limbs as arthritis score
vs. time in days. Statistical differences among the groups in clinical disease scores were
determined by one-way analysis of variance followed by Fisher’s least significant
difference. All analyses were performed using StatView (SAS Institute, Cary, NC). The
mice were sacrificed on day 55. For histopathology analyses 4 mice from each group of
mice described above were used. Their hind limbs were removed and fixed using 10%
formalin before decalcification of the bone tissue. These samples were embedded in paraffin
and sectioned into 5 µM thick slices for histological analysis. Sections were stained with
haematoxylin and eosin (H & E).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A) Crystal structure of CD2 showing adhesion domain. Secondary structure elements that
are important in binding to CD58 are labeled (F, C, C', C") with residue numbers. B)
Sequence of fragments of secondary structure of CD2 that are important in binding to CD58
(F and C β-strands) are shown with residue numbers. Peptides were designed based on these
results as discussed in the text.
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Fluorescence assay for binding of fluorescently labeled P4 to Caco-2 cells bearing CD58.
Concentration dependence of binding of peptide is shown. Error bars indicate standard error
of the mean (SEM). P < 0.05 for 50 µM and 100 µM FITC-P4 when compared with only
cells.
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Fluorescence images showing binding of A) fluorescently labeled P4 and B) FITC-anti-
CD58 to Caco-2 cells. Magnification 20×.
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Antibody (FITC-antiCD58) binding inhibition of P3 and P4 to Caco-2 cells bearing CD58
protein. Peptide was concentration was 180 µM. Error bars indicate standard error of the
mean (SEM). P < 0.05 for P3, P4 when compared with control peptide inhibition.
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Competitive binding of anti-CD58 and FITC-P4. The concentration of anti-CD58 was kept
constant (6.25 µg/mL) and the concentration of FITC-P4 was varied. For comparison, 100
µM of FITC-P4 in the absence of antibody (−) is also shown. P < 0.05 for 50 µM FITC P4
when compared to 100 µM in the absence of antibody. P >0.05 for 200 and 100 µM FITC
P4 in the presence of antibody when compared to 100 µM in the absence of antibody.
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Cell viability of Caco-2 cells on treating different concentration of peptides. At the highest
peptide concentration used in the study, the cells are still viable, indicating that the peptides
are not toxic to cells. P< 0.05 for peptide treated cells compared to DMSO treated cells.
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1D NMR spectrum of A) P3 in the presence (ratio of protein to peptide was 1:80) and
absence of protein CD58, B) control peptide in the presence (1:80 ratio of protein to peptide)
and absence of protein, indicating the binding of P3 to protein CD58.
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A) Docked structure of P3 to CD58 protein domain D1. Two clusters with low docking
energy are shown in the figure. B) Docked structure of P3 on the adhesion domain of CD58.
Detailed interactions of P3 and CD58 protein are shown here. Amino acids of the peptide
are labeled with three letter code, and amino acids of protein CD58 are labeled with single
letter code for clarity. Interaction of Tyr3 and Asp4 and Pro5 of the peptide with K34 and
F46 of protein CD58 are shown.
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The effect of P3 on collagen-induced arthritis in mice. Five groups of eight mice were used
in the study. P3 was injected from days 22 to 32 on alternative days. PBS-phosphate-
buffered saline, a control peptide (CII-3). Dosing of the peptide was 2.5 mg/kg in PBS. Data
shows average change in paw volumes of all mice in the group ± SEM (n = 8). The standard
errors of mean bars are plotted only on one side (top side) for clarity. P <0.01 for P3 treated
mice when compared to PBS and control peptide treated mice. There was a significant
difference between the average scores of mice injected with control peptide (G3) and
arthritic mice treated with peptide P3 (G4).
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Representative tissue sections taken from G1, G2 and G4 group of mice (see Table 2 for
grouping) are shown in the figure. A) Normal phalangeal joints of hind foot of control
mouse without intradermal injection of type II collagen (CII) (4 mice in each group).
Cartilaginous surfaces are intact and smooth (arrows) with normal synovium (arrowheads)
and clear joint space (*). B) Severely arthritic phalangeal joint of hind foot of mouse
intradermally injected with CII without further treatment. Marked cartilaginous and bone
erosion (arrows) are present with severe pannus formation (P) and synovitis (S). The
articular space (A) is filled with tissue detritus, fibrin, and mixed inflammatory cells. C)
Mildly arthritic phalangeal joint of hind foot of mouse intradermally injected with CII and
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treated with P3. Both cartilaginous surfaces of articulating phalanges are eroded (arrows)
with slight synovial hyperplasia (S) but lacking both invasive pannus and significant
inflammatory exudate. H&E staining. Original magnification ×100.
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Table 1
Sequences of the Peptides that are Derived from Human CD2 Protein.
Code Sequence a Comment
2 Cyclo(1,11) H-E1S2I3Y4D5P6G7D8D9I10K11-OH Cyclized by side chain of E1 and K11
3 Cyclo(1,10) E1I2Y3D4P5G6D7D8I9K10 Main chain cyclization
4 Cyclo(1,10) H-E1I2Y3D4P5G6D7D8I9K10-OH Cyclized by side chain of E1 and K10
Control KGKTDAISVKAI-NH2 Reversal of sequence and replacement of Y81 and Y86 by Ala
FITC-4 FITC-Cyclo(1,10) H-E1I2Y3D4P5G6D7D8I9K10-OH Fluoresceineisothiocyanate attachment at N-terminal via amino hexanoic acid
(Ahx)
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Table 2
Grouping of mice for in vivo studies. n=8 used for arthritis score, n=4 used for histopathology analysis.
Group Description
G1 Control group—Normal mice, no arthritis
G2 Arthritic mice-injected with collagen, no treatment
G3 Arthritic mice treated with control peptide
G4 Arthritic mice treated with P3 peptide
G5 Arthritic mice treated with PBS
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